Trial Profile
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms STERIMGLI
- 07 Sep 2023 Results evaluating the safety and the recommended phase II dose , published in the Oncologist
- 20 Apr 2023 Planned End Date changed from 1 Dec 2024 to 1 Apr 2026.
- 20 Apr 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Apr 2026.